ESR1 and breast carcinoma: TNBC, by definition, lacks the three typical surface markers and is thus refractory to common therapeutic targets of breast cancer, including the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), which severely limits its therapeutic options and justifies continued efforts to develop additional TNBC-specific treatments.